281
Participants
Start Date
February 28, 2009
Primary Completion Date
July 31, 2015
Study Completion Date
July 31, 2015
Anti-PDL-1 antibody
Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
Anti-PDL-1 antibody
Solution, Intravenous, 0.3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
Anti-PDL-1 antibody
Solution, Intravenous, 1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
Anti-PDL-1 antibody
Solution, Intravenous, 3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
Anti-PDL-1 antibody
Solution, Intravenous, 10 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
Roswell Park Cancer Institute, Buffalo
Johns Hopkins University, Baltimore
Emory University, Atlanta
Ohio State University, Columbus
University Of Cincinnati, Cincinnati
Mayo Clinic, Rochester
University Of Chicago, Chicago
Oncology Consultants, Pa, Houston
The University Of Texas, Houston
The Angeles Clinic & Research Institute, Los Angeles
Fred Hutchinson Cancer Center, Seattle
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY